Factive gemifloxacin mesylate regulatory update

Menarini said it withdrew an MAA for Factive gemifloxacin to treat mild to moderate community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis. The company said it withdrew the ap...